Ask AI

Advancing Pharmacist Excellence in Relapsed/Refractory Multiple Myeloma: Assessing and Managing AEs Associated With Bispecific Antibody Therapy

Text Module
Text Module Start Activity
This activity is available for 0.50 CME/CE credit(s).

Released: August 25, 2026

Expiration: February 24, 2027

See Activity Collection

Bispecific antibody therapy continues to rapidly change the care of patients with R/R multiple myeloma, but these drugs are associated with adverse events that must be managed for patients to remain on therapy long term. In this text module, experts provide learners with illustrated evidence-based information on CRS, ICANS, and infection. Key insights on what symptoms to monitor in patients during step-up dosing and maintenance phases are provided. Details about formulary management, REMS requirements, and standardized protocols used in multidisciplinary patient care are also discussed. 

AEs of BsAbs in RRMM

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

How many people with MM do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

BH started initial treatment with linvoseltamab and began experiencing a fever of 101.4°F and generalized muscle aches. BH went to the emergency department, and they called you for guidance on the most appropriate management.

What would you recommend as the appropriate guideline-based management for the cytokine release syndrome (CRS) that BH is experiencing?

4.

An important part of therapy is counseling patients on expectations when they receive treatment with a bispecific antibody (BsAb) for relapsed/refractory (R/R) multiple myeloma (MM). 

During the pharmacy education visit, patient BH expresses concern about the risk of infection with linvoseltamab. What prophylaxis measures should be discussed with patient BH?